Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04511715

Intravitreal Bevacizumab for Nonproliferative Diabetic Retinopathy

Non-proliferative Diabetic Retinopathy Clinical Trial

Official title:
Efficacy and Safety of Intravitreal Bevacizumab for the Improvement of Severe Non-proliferative Diabetic Retinopathy Without DME: a Randomized Clinical Trial

Clinical Trial Summary

In this randomized clinical trial, 100 eyes with nonproliferative diabetic retinopathy will be included and divided randomly into 2 groups: Intravitreal Bevacizumab group (50 eyes) that receive 6 bimonthly intravitreal bevacizumab, and control group (50 eyes) that undergo regular follow-up for Diabetic Retinopathy. Diabetic macular edema (DME) will be treated independently in all groups by intravitreal bevacizumab. Primary outcome will be the percentage of patients with progression of 2 or more stages through international diabetic retinopathy staging. The secondary measures will be changes in best corrected visual acuity (BCVA) and central macular thickness (CMT), and number of examinations and injection.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04511715
Study type Interventional
Source Shahid Beheshti University of Medical Sciences
Contact Homayon Nikkhah, MD
Phone 009822591616
Email labbafi@hotmail.com
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date September 1, 2020
Completion date November 1, 2021
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT02388984 - Phase III Study of Compound Danshen Dripping Pills to Treat Diabetic Retinopathy Phase 3
Completed NCT01646047 - Diabetes Visual Function Supplement Study N/A
Not yet recruiting NCT01107132 - Blood-retinal Barrier Imaging and Neuropsychiatric Sequela in Type 2 Diabetes Mellitus N/A
Active, not recruiting NCT05681884 - Safety and Efficacy of Faricimab in Patients With NPDR Phase 2
Recruiting NCT06270836 - A Study to Evaluate the Efficacy and Safety of Tarcocimab Tedromer Compared With Sham Treatment in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) Phase 3
Completed NCT01853072 - Nepafenac Once Daily for Macular Edema - Study 1 Phase 3
Completed NCT01872611 - Nepafenac Once Daily for Macular Edema - Study 2 Phase 3
Completed NCT02096874 - Bevacizumab and Peripheral Retinal Changes on Wide Field Angiography in Diabetic Macular Edema Phase 4
Not yet recruiting NCT04000789 - The Effect of Combination of Vitamin A, Vitamin E, Sodium Hyaluronate 0.15% Eye Drop Compared With Sodium Hyaluronate 0.1% Eye Drop to Tear Film Stability and Conjunctival Goblet Cells Density in Patient With Non-Proliferative Diabetic Retinopathy (NPDR), and Proliferative Diabetic Retinopathy (PDR) N/A
Active, not recruiting NCT05695417 - Study to Evaluate the Safety, Tolerability, and Efficacy of OTX-TKI in Subjects With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy Phase 1
Recruiting NCT05222633 - Anti-VEGF in Real-world
Completed NCT02062034 - Efficacy of Ubiquinone and Combined Antioxidant Therapy in Non-proliferative Diabetic Retinopathy Phase 2
Completed NCT02435862 - A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy Phase 2
Terminated NCT05066230 - A Study to Evaluate the Efficacy and Safety of Intravitreal KSI-301 in Participants With Moderately Severe to Severe Non-proliferative Diabetic Retinopathy (NPDR) Phase 3
Recruiting NCT05393284 - Phase 2 Spectra Study to Evaluate the Safety and Efficacy of OPL-0401 in Patients With Diabetic Retinopathy Phase 2
Completed NCT01571232 - Ozurdex for Treatment of Recalcitrant Diabetic Macular Edema Phase 2